Iconovo Cash Flow Conversion Efficiency
Iconovo cash flow conversion efficiency. Based on the latest financial reports, Iconovo (ICO) has a cash flow conversion efficiency ratio of -0.057x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-8.48 Million ≈ $-913.01K USD) by net assets (Skr149.29 Million ≈ $16.07 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Iconovo (2016–2025)
Cash flow conversion efficiency of Iconovo from 2016 to 2025. This chart illustrates how Iconovo's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ICO live share price for real-time trading data and today's change.
Iconovo Cash Flow Conversion Ratio Explained
Iconovo cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Iconovo Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Iconovo ranked by their cash flow conversion efficiency. Also see Iconovo (ICO) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Greenland Mines Ltd
NASDAQ:GRML
|
-0.113x |
|
Avillion Bhd
KLSE:8885
|
-0.004x |
|
Spolytech Co. Ltd
KQ:050760
|
0.084x |
|
Eurocastle Investment Ltd
AS:ECT
|
-0.015x |
|
Oceanic Beverages Co Inc
TW:1213
|
-0.090x |
|
Atlantis Yatirim Holding AS
IS:ATSYH
|
-0.001x |
|
Cannabist Company Holdings Inc
NEO:CBST
|
0.161x |
|
Sri Adhikari Brothers Television Network Limited
NSE:SABTNL
|
-36.713x |
Annual Cash Flow Conversion Efficiency for Iconovo (2016–2025)
The table below shows the annual cash flow conversion efficiency of Iconovo from 2016 to 2025. Review ICO free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr117.92 Million ≈ $12.69 Million |
Skr-31.87 Million ≈ $-3.43 Million |
-0.270x | -42.31% |
| 2024-12-31 | Skr129.21 Million ≈ $13.91 Million |
Skr-24.54 Million ≈ $-2.64 Million |
-0.190x | +44.15% |
| 2023-12-31 | Skr113.53 Million ≈ $12.22 Million |
Skr-38.60 Million ≈ $-4.15 Million |
-0.340x | +30.53% |
| 2022-12-31 | Skr89.29 Million ≈ $9.61 Million |
Skr-43.70 Million ≈ $-4.70 Million |
-0.489x | -509.02% |
| 2021-12-31 | Skr137.03 Million ≈ $14.75 Million |
Skr-11.01 Million ≈ $-1.19 Million |
-0.080x | +53.31% |
| 2020-12-31 | Skr92.73 Million ≈ $9.98 Million |
Skr-15.96 Million ≈ $-1.72 Million |
-0.172x | -54.97% |
| 2019-12-31 | Skr108.79 Million ≈ $11.71 Million |
Skr-12.08 Million ≈ $-1.30 Million |
-0.111x | -599.12% |
| 2018-12-31 | Skr63.99 Million ≈ $6.89 Million |
Skr-1.02 Million ≈ $-109.38K |
-0.016x | +86.88% |
| 2017-12-31 | Skr31.52 Million ≈ $3.39 Million |
Skr-3.82 Million ≈ $-410.77K |
-0.121x | -117.56% |
| 2016-12-31 | Skr8.73 Million ≈ $939.49K |
Skr6.02 Million ≈ $647.74K |
0.689x | -- |
About Iconovo
Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreeme… Read more